ReviewBiomaterials research2026
Nanozymes in Tumor Microenvironment Modulation for Cancer Therapy.
Review in Biomaterials research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor microenvironment (TME) plays a central regulatory role in malignant tumor progression and therapeutic resistance, and its complexity and dynamic heterogeneity markedly limit the efficacy of current treatment strategies. Therefore, the development of novel functional materials capable of effectively remodeling the TME and alleviating immunosuppression and therapeutic tolerance has become an important research direction in cancer therapy. In recent years, nanozymes, as a class of nanomaterials with enzyme-mimicking catalytic activity, have shown broad potential in TME intervention and the enhancement of cancer therapy owing to their excellent physicochemical stability, tunable structural properties, and multiple biomimetic enzyme-like activities. This review systematically summarizes recent advances in nanozyme-mediated regulation of the TME. First, the basic concepts, catalytic properties, and functional classifications of nanozymes are introduced. Subsequently, the mechanisms by which nanozymes remodel the TME and enhance cancer therapy are discussed from the key dimensions of the redox microenvironment, metabolic microenvironment, and immune microenvironment. Finally, the major challenges, barriers to clinical translation, and future development directions in this field are highlighted. This review aims to provide a theoretical basis and research perspectives for the further study, rational design, and translational application of nanozymes in cancer therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.